​

Sagimet Biosciences Stock (NASDAQ:SGMT)

ForecastOwnershipFinancialsChart
Sagimet Biosciences by TradingView

Previous Close

$4.83

52W Range

$1.73 - $11.41

50D Avg

$5.67

200D Avg

$7.08

Market Cap

$149.43M

Avg Vol (3M)

$558.17K

Beta

3.40

Div Yield

-

SGMT Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jul 17, 2023

Website

SGMT Performance

SGMT Financial Summary

Dec 25Dec 24Dec 23
Revenue--$2.00M
Operating Income$-56.89M$-54.45M$-30.74M
Net Income$-51.04M$-45.57M$-27.88M
EBITDA$-56.89M$-45.57M$-30.74M
Basic EPS$-1.58$-1.45$-1.53
Diluted EPS$-1.58$-1.45$-1.53

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
FHTXFoghorn Therapeutics Inc.
ARCTArcturus Therapeutics Holdings Inc.
HUMAHumacyte, Inc.
AVIRAtea Pharmaceuticals, Inc.
ASMBAssembly Biosciences, Inc.
ACHVAchieve Life Sciences, Inc.
VYGRVoyager Therapeutics, Inc.
TRDAEntrada Therapeutics, Inc.
IMRXImmuneering Corporation
ZURAZura Bio Limited